Vertex One Asset Management’s Kyntra Bio KYNB Stock Holding History

Vertex One Asset Management’s Portfolio KYNB Stock Details KYNB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q3	–	Sell	-3,200	Closed	-$1.31M	–	118
2016 Q2	$1.31M	Sell	3,200 -9,200	-74%	-$4.21M	0.21%	75
2016 Q1	$6.6M	Buy	12,400 +8,400	+210%	+$4.19M	0.96%	30
2015 Q4	$3.05M	Buy	+4,000	New	+$2.65M	0.41%	66

Other funds holding KYNB

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

WRF

Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return

JHIU

Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vertex One Asset Management's KYNB Position: Q3 2016 in Review

Vertex One Asset Management sold out of Kyntra Bio (KYNB) in Q3 2016, closing a stake of 3,200 shares — an estimated $1.31M sold.

Vertex One Asset Management first reported a position in KYNB in Q4 2015 and held it in 3 quarters. The position peaked at $6.6M in Q1 2016. 133 funds tracked by Wall St. Rank hold KYNB as of Q3 2016.

Vertex One Asset Management reported no remaining Kyntra Bio position as of Q3 2016 after selling out during the quarter.
Vertex One Asset Management sold 3,200 Kyntra Bio shares in Q3 2016, an estimated $1.31M.
Vertex One Asset Management first reported a position in Kyntra Bio in Q4 2015 and held it in 3 quarters.
Vertex One Asset Management's Kyntra Bio position peaked at $6.6M in Q1 2016.
133 funds tracked by Wall St. Rank held Kyntra Bio as of Q3 2016.

Based on Vertex One Asset Management's 13F filing for Q3 2016, filed 14 Nov 2016.